<code id='833581C760'></code><style id='833581C760'></style>
    • <acronym id='833581C760'></acronym>
      <center id='833581C760'><center id='833581C760'><tfoot id='833581C760'></tfoot></center><abbr id='833581C760'><dir id='833581C760'><tfoot id='833581C760'></tfoot><noframes id='833581C760'>

    • <optgroup id='833581C760'><strike id='833581C760'><sup id='833581C760'></sup></strike><code id='833581C760'></code></optgroup>
        1. <b id='833581C760'><label id='833581C760'><select id='833581C760'><dt id='833581C760'><span id='833581C760'></span></dt></select></label></b><u id='833581C760'></u>
          <i id='833581C760'><strike id='833581C760'><tt id='833581C760'><pre id='833581C760'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:knowledge    - browse:18
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge